Clinical Trial Update: Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia [Phase 3]

View source ↗

Summary

Phase 3 trial update for a novel tetravalent dengue vaccine in children aged 2–14 in Asia; the study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue
• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Dengue vaccine (tetravalent)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue, Dengue Fever | Phase 3 | Status: COMPLETED | Results posted: 2015-11-16